JAK2 and myeloproliferative neoplasm: One subject, C12, harbored the JAK2 V617F mutation (VAF 0.82%) (Fig. 2b, c), a clinically relevant variant identified in myeloproliferative neoplasms (MPNs) that has also been associated with ~12-fold increased risk of CVD and thrombosis risk5,14–17.